Riociguat: Something new in pulmonary hypertension therapeutics?
Shanmugam E1, Jena A1, George M1.
Journal of pharmacology & pharmacotherapeutics.J Pharmacol Pharmacother.2015 Jan-Mar;6(1):3-6. doi: 10.4103/0976-500X.149132.
Pulmonary hypertension (PH) continues to be a disease that is associated with woeful outcomes. The search for an ideal drug molecule for PH led to the discovery of riociguat, which is a first-in-class drug molecule that activates soluble guanylate cyclase. We conducted a systematic literature search